sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
- CAS NO.：496807-11-5
- Empirical Formula: C24H31NaO5
- Molecular Weight: 422.5
- Update Date: 2024-07-02 08:55:11
![sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate Structural](https://img.chemicalbook.in/CAS/20180601/GIF/496807-11-5.gif)
What is sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate?
Biological Activity
Beraprost sodium, a prostacyclin analog, is a stable and orally active PGI2 prodrug. It is an effective vasodilator, which has the potential to study pulmonary hypertension by dilating renal blood vessels and improving microcirculation.
in vitro
Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity. Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment let VE-cadherin at regions of cell–cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions.
< /b>
in vivo
Beraprost sodium (oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis .
| Animal Model: | 6-8-week-old C57Bl/6J Male Mice |
| Dosage: | 0.6 mg/kg |
| Administration: | Oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days |
| Result: < /td> | Mitigated the development of renal interstitial fibrosis. |
storage
Store at -20°C
Properties of sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
| storage temp. | Store at -20°C |
| solubility | DMSO: 250 mg/mL (594.57 mM) |
| form | Solid |
| color | White to light yellow |
Safety information for sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
Computed Descriptors for sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
New Products
8-Bromoisoquinoline 3-pyridine carboxaldehyde 7-bromoquinoxalin-2(1H)-one 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-ylidene)methyl]piperidine 3-Pyridineacetonitrile, α-amino-, hydrochloride (1:1) Trans-methyl 4-aminocyclohexane- carboxylate HCl 4-[2-(DIMETHYLAMINO)ETHOXY]BENZYLAMINE Xanomeline Suzetrigine 5-(5,5-Dimethyl-1,3,2-dioxaborinan-2-yl)-3-methyl-1,3-benzoxazol-2(3H)-one Dimethyl 4-aminothiophene-2,3-dicarboxylate hydrochloride Remibrutinib 1H-Indole-1-carboxylic acid, 5-hydroxy-7-methyl-, 1,1-dimethylethyl ester N N N'Trimethyl ethylenediamine Variamine Blue B Diazonium salt Lead II Bromide N N' DimethylEthylenediamine Ethyl Methanesulfonate N Ethylmethylamine Zinc Chloride Solution (All Grades) Calcium Alphaketoglutarate* L-Glycine methyl ester.HCl H-Ser(t-Bu)-Ser(t-Bu)-Gly-OH Fmoc-L-Glu(OtBu)-OH.H2ORelated products of tetrahydrofuran
You may like
-
2-Fluoro-6-iodobenzoic acid 111771-08-5 98+View Details
111771-08-5 -
3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 98+View Details
2304754-51-4 -
2,3-Difluoro-6-methoxybenzyl Chloride 1073435-67-2 98+View Details
1073435-67-2 -
1589503-95-6 98+View Details
1589503-95-6 -
2-(6-(benzyloxy)-3,4-dihydronaphthalen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 98+View Details
2477812-43-2 -
Phenylazomalononitrile 98+View Details
6017-21-6 -
KT-474 98+View Details
2432994-31-3 -
7646-85-7 Zinc Chloride Solution (All Grades) As requiredView Details
7646-85-7